Download the Complete Report Here By Brandon Hornback Aurora Cannabis Inc. (NASDAQ: ACB) smoked another quarter, led by ...

Aurora Cannabis Inc. is rated a Buy with 40% upside in current levels and expects solid growth in medical cannabis sales.

Aurora Cannabis (ACB) delivered earnings and revenue surprises of +200.00% and +2.88%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Q2 2026 Earnings Call November 5, 2025 8:00 AM ESTCompany ParticipantsSimona King - Chief Financial OfficerMiguel Martin - ...

Shares of Aurora Cannabis Inc. ACB slid 2.24% to $4.36 Thursday, on what proved to be an all-around poor trading session for ...

Expands YoY Global Medical Cannabis Net Revenue 1 by 15% to Record $70.5 million Increases International Medical Cannabis Net Revenue 1 by 22% to Record ...

Canadian pot producer Aurora Cannabis Inc , on Tuesday forecast first-quarter revenue below analysts' estimates, sending its U.S-listed shares tumbling 15%.

Detailed price information for Aurora Cannabis Inc (ACB-Q) from The Globe and Mail including charting and trades.

Detailed price information for Aurora Cannabis Inc (ACB-Q) from The Globe and Mail including charting and trades.

Aurora Cannabis Inc. reported fiscal second-quarter 2026 revenue of $90.4 million, an 11% increase year-over-year, driven largely by record global medical marijuana sales. The Edmonton-based company ...

Looking ahead, Aurora expects its third-quarter 2026 consolidated revenue to increase year over year, led by 8% to 12% growth in global medical cannabis sales. Management also projects continued ...

Aurora Cannabis (US) ( ($ACB) ) has released its Q2 earnings. Here is a breakdown of the information Aurora Cannabis (US) presented to its ...